• Agreement to Allow Generation of Pre-Clinical Human Models

News & Views

Agreement to Allow Generation of Pre-Clinical Human Models

Under a new licensing agreement DefiniGEN will combine its best-in-class iPSC (induced Pluripotent Stem Cell) differentiation platform with CRISPR/Cas9 technology to generate a range of innovative preclinical human models.

"The company’s gene editing technical portfolio has been further strengthened by licensing of this cutting-edge technology and will allow us to produce a range of innovative and unique preclinical human models for the drug discovery sector," stated Dr Marcus Yeo, CEO of DefiniGEN. "These tools will enable our customers to optimise the preclinical development of therapeutics for multiple rare liver diseases, Type 2 diabetes and non-alcoholic fatty liver disease (NAFLD)."

"The outlook for gene edited iPSCs to become a major contributor to new drug discovery and safer more effective treatments istremendous," commented Eric Rhodes, CEO of ERS Genomics. "DefiniGEN has been a leader in the iPSC space for several years now and we’re thrilled to see them bolster their platform through this agreement."

With this license, DefiniGEN has the right to produce CRISPR-edited cell models, strengthening its core capabilities and keeping DefiniGEN at the forefront of metabolic disease modelling. Financial details of the agreement were not disclosed


Digital Edition

LMUK 49.7 Nov 2024

November 2024

News - Research & Events News   - News & Views Articles - They’re burning the labs... Spotlight Features - Incubators, Freezers & Cooling Equipment - Pumps, Valves & Liquid Hand...

View all digital editions

Events

analytica China

Nov 18 2024 Shanghai, China

Pharma Asia

Nov 20 2024 Karachi, Pakistan

Turkchem

Nov 27 2024 Istanbul, Turkey

Smart Factory Expo 2025

Jan 22 2025 Tokyo, Japan

Instrumentation Live

Jan 22 2025 Birmingham, UK

View all events